Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 18, 2001
The study, which used ViroLogic's rapid, direct and sensitive drug resistance test, PhenoSense(TM) HIV, will be presented as a latebreaker abstract today at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). HIV drug resistance is the leading cause of HIV treatment failure and the data presented here indicate that the problem is considerably larger than previously believed.
"This is the first comprehensive study to show just how prevalent drug resistance has become in the U.S., and underscores the need for physicians and patients to understand both the magnitude of the resistance problem and the therapeutic approaches available to address it," said Douglas Richman, M.D., Professor of Pathology and Medicine, University of California, San Diego and Chief, Virology Section and Director, Research Center for AIDS and HIV Infection, VA San Diego Healthcare System, who presented the study today. "Drug resistance testing should become a standard part of care. Physicians can use the valuable information provided by drug resistance testing to decide if and when treatment interventions are appropriate and to help patients avoid treatment failure."
"ViroLogic, along with our distribution partners, will use this important data to continue to educate our customers about the vital need for drug resistance testing, and expect it to help fuel the continued growth of our business," said Bill Young, ViroLogic's Chairman and CEO.
Researchers led by Dr. Richman used PhenoSense HIV to measure drug resistance among participants in the HIV Cost and Service Utilization Study (HCSUS), a longitudinal study representing the 209,000 HIV-infected adults in the United States who were receiving medical care in 1996 and were alive at the end of 1998 or early 1999. This survey was conducted more than two years after highly active antiretroviral therapies (HAART) were introduced as standard treatment regimens, indicating that widespread resistance occurred frequently despite the use of potent new classes of HIV drugs.
The study found HIV drug resistance to nucleoside reverse transcriptase inhibitors (NRTI's) in 70 percent of tested patients, to non-nucleoside reverse transcriptase inhibitors (NNRTI's) in 31 percent of patients, and to protease inhibitors (PI's) in 42 percent of patients. Resistance was not limited to those who have been heavily treated. While HIV in 87 percent of subjects taking antiretroviral therapy exhibited some drug resistance, virus in 41 percent of patients not receiving therapy also showed signs of drug resistance. Thus, drug resistant virus may exist in patients who have not started therapy or who have discontinued prior therapy. This finding may have significant implications not only for previously treated patients, but also for newly infected individuals, who increasingly are infected with drug resistant strains of the virus.
"The bad news here is that HIV is a highly adaptable virus that can outsmart the drugs we now have available," said Dr. Richman. "The good news is that there are approaches physicians and patients can employ to limit the impact of resistance and maintain viral suppression."
Conference Call Details
The Company will hold a conference call today to discuss the latebreaker, "The Prevalence of Antiretroviral Drug Resistance in the U.S.," at 12:00 pm Eastern time. The call will be hosted by Bill Young and Dr. Richman. To participate, please dial 800-360-9865 ten minutes prior to the start of the call. To listen to a live webcast of the call visit http://www.virologic.com.
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized medicine and pharmacogenomics, helping to make them realities in healthcare around the world today. The Company discovers, develops and markets innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. Its leading expertise in virology, molecular biology, clinical research, engineering, information systems, and quality assurance has resulted in technology to assess drug resistance and susceptibility in viruses that cause these diseases, which affect millions of people worldwide.
The Company's current products are designed to optimize HIV/AIDS treatment regimens, providing physicians with important information to help select appropriate drugs for their patients and leading to better outcomes and reduced costs. These products are also being used by major pharmaceutical companies to develop new and improved antiviral therapeutics targeted at emerging drug-resistant viruses. More information about the Company and its technologies is available at http://www.virologic.com or http://www.phenosense.com.
Certain statements in this press release are forward-looking, including statements relating to the Company's product development efforts. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to whether ViroLogic's products will achieve market acceptance, whether payers will authorize reimbursement for our products, whether we will be able to expand our sales and marketing capabilities, whether the FDA or any other agency will decide to regulate our products or services, whether we will encounter problems or delays in automating our process, whether we will successfully introduce new products using our PhenoSense technology, whether intellectual property underlying our technology is adequate, whether we are able to build brand loyalty, whether we will be able to raise sufficient capital and other risks and uncertainties detailed from time to time in our reports to the Securities and Exchange Commission, including our report on Form 10-K for the year ended December 31, 2000.
011218
PR011237
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .